ライフサイエンスコーパス: L-carnitine

1 infection or by dietary supplementation with l-carnitine.

2 Proposed to study intravenous L-carnitine.

3 ch as four vitamins, uric acid, creatine and l-carnitine.

4 convulsants (topiramate), coenzyme Q-10, and L-carnitine.

5 ond study consisted of oral ingestion of 3 g l-carnitine.

6 yl-CoAs to acylcarnitines in the presence of l-carnitine.

7 10), Ginkgo biloba, nicotinamide, and acetyl-L-carnitine.

8 cyl-CoA to acylcarnitines in the presence of l-carnitine.

9 mproved in both arms compared with baseline (L-carnitine: -0.96, 95% CI, -1.32 to -0.60; placebo: -1.

10 ase in catalytic efficiency (kcat/Km) toward L-carnitine (1,620-fold) and shifts the catalytic discri

11 All patients received L-carnitine, 500 mg/d.

12 f 80 g carbohydrate (Control, n=6) or 1.36 g L-carnitine + 80 g carbohydrate (Carnitine, n=6).

13 L-carnitine, a popular complementary and alternative med

14 l-CoAs to acyl carnitines in the presence of l-carnitine, a rate-limiting step in the transport of lo

15 tabolism by intestinal microbiota of dietary L-carnitine, a trimethylamine abundant in red meat, also

16 , the short- and long-term effects of acetyl-L-carnitine administration on peripheral nerve polyols,

17 in healthy humans, by dietary or intravenous L-carnitine administration.

18 Acetyl-L-carnitine (ALC) is a natural compound involved in neur

19 elationships between COX-mediated and acetyl-L-carnitine (ALC)-sensitive defects that contribute to f

20 We noted that acetyl-L-carnitine (ALC, a cofactor of cPT1 and cPT2) prevented

21 d rats two mitochondrial metabolites, acetyl-l-carnitine (ALCAR) [0.5% or 0.2% (wt/vol) in drinking w

22 ed for 7 weeks with the CAT substrate acetyl-l-carnitine (ALCAR) and/or the mitochondrial antioxidant

23 gonist AICAR or the antioxidant agent acetyl-l-carnitine (ALCAR) restored SIRT3 expression and activi

24 were monitored after feeding old rats acetyl-L-carnitine (ALCAR).

25 dress whether the dietary addition of acetyl-l-carnitine [ALCAR, 1.5% (wt/vol) in the drinking water]

26 Twelve weeks of daily l-carnitine and carbohydrate feeding in humans increases

27 Here we determined the influence of L-carnitine and carbohydrate feeding on energy metabolis

28 4C]acetylcarnitine in the presence of excess L-carnitine and carnitine acetyltransferase.

29 of dietary phosphatidylcholine, choline, and L-carnitine and CVD risk.

30 Unlabeled L-carnitine and its structurally related analogues signi

31 on of PCoA concentration, in the presence of L-carnitine and malate, were performed.

32 rial efficiently identifies the best dose of L-carnitine and provides clear guidance regarding whethe

33 ing as probes both the endogenous substrate (l-carnitine) and the organic cation tetraethylammonium,

34 Endogenous antioxidants, such as ghrelin, L-carnitine, and annexin-1 attenuate the oxidative-stres

35 r for discriminating choline, acetylcholine, L-carnitine, and glycine betaine effectively.The choline

36 ign choline acetyltransferase to accommodate L-carnitine as an acceptor of the acetyl group.

37 catalytic discrimination between choline and L-carnitine by >390,000 in favor of the latter substrate

38 aine (from reduction of crotonobetaine) from L-carnitine by enteric bacteria has been demonstrated in

39 esults suggest that pharmacological doses of L-carnitine can activate GRalpha and, through this mecha

40 Dietary intake of L-carnitine can promote cardiovascular diseases in human

41 including phosphatidylcholine, choline, and L-carnitine, can enter into a microbial metabolic pathwa

42 is a homotrimeric antiporter that exchanges l-carnitine (CRN) with gamma-butyrobetaine (GBB) across

43 ce TMAO levels in mice fed a high-choline or L-carnitine diet.

44 d that the pooled estimate is independent of L-carnitine dose (slope: -0.30; 95% CI: -4.19, 3.59; p =

45 The addition of l-carnitine enabled the metabolic channeling of acyl-CoA

46 positive effect, thus chiral recognition of l-carnitine enantiomers is extremely important in biolog

47 g7 knockdown using small interfering RNA; or L-carnitine, essential for transport of fatty acids into

48 ity and type 2 diabetes but requires chronic L-carnitine feeding on a daily basis in a high-carbohydr

49 er adjuvant therapies such as ascorbic acid, L-carnitine, folic acid, vitamin D, androgens, and other

50 osting mitochondrial membrane potential with l-carnitine-fostered dendrite at the expense of synapse

51 ne transporter (CaiT) is an ion-independent, l-carnitine/gamma-butyrobetaine antiporter belonging to

52 Short-term prevention (4 mo) with acetyl-L-carnitine had no effects on nerve polyols, but correct

53 These results demonstrate that acetyl-L-carnitine has a preventive effect on the acute Na+/- K

54 ne retention observed after a single dose of l-carnitine in vegetarians was not attributable to incre

55 l-carnitine infusion with hyperinsulinemia, l-carnitine infusion in the presence or absence of hyper

56 15% increase (P < 0.05) in muscle TC during l-carnitine infusion with hyperinsulinemia, l-carnitine

57 ght healthy men underwent 5 h of intravenous L-carnitine infusion with serum insulin maintained at fa

58 excretion was 55% less in vegetarians after l-carnitine ingestion.

59 l-Carnitine is a vitamin-like amino acid derivative, whi

60 L-carnitine is an essential nutrient with a major role i

61 The mechanism of intestinal uptake of L-carnitine is controversial.

62 choline, phosphatidylcholine (lecithin), and l-carnitine, is elevated in chronic kidney diseases (CKD

63 ative, rapidly acting antidepressant, acetyl-l-carnitine (LAC) in the drinking water opposed the dire

64 , modulating histone acetylation with acetyl-L-carnitine (LAC) or acetyl-N-cysteine (NAC) rapidly inc

65 at an epigenetic and energetic agent, acetyl-l-carnitine (LAC, oral administration), rapidly rescued

66 l-Carnitine (LC) exerts beneficial effects in arterial h

67 r preventing drug-induced hearing loss using l-carnitine (LCAR), a safe micronutrient that plays a ke

68 Plasma L-carnitine levels in subjects undergoing cardiac evalua

69 piration supported by succinate or palmitoyl-L-carnitine/malate but not pyruvate/malate), indicative

70 In procaryotes, L-carnitine may be used as both a carbon and nitrogen so

71 r its esterified derivatives, such as acetyl-L-carnitine, may have deleterious effects.

72 rosis and glycerophospholipid metabolism and L-carnitine metabolism in the development of CRF.

73 ed number of available Lp(a)-targeted drugs, L-carnitine might be an effective alternative to effecti

74 There is evidence that, at high doses, L-carnitine might mimic some of the biological activitie

75 s of this effect, we tested the influence of L-carnitine on glucocorticoid receptor-alpha (GRalpha) f

76 We aimed to assess the impact of L-carnitine on plasma Lp(a) concentrations through syste

77 o a shift toward increased expression of the L-carnitine palmitoyltransferase I isoform.

78 iety, namely choline/phosphatidylcholine and L-carnitine, participate in the development of atheroscl

79 ane transport of palmitoylcarnitine and free L-carnitine - processes that are necessary for an indire

80 s (enriched in fat, phosphatidylcholine, and L-carnitine) promote inflammation and atherosclerosis th

81 acetyl group from acetyl-CoA to choline and L-carnitine, respectively.

82 Intervention with acetyl-L-carnitine resulted in 76% recovery of the conduction d

83 Metabolites derived from dietary choline and L-carnitine, such as trimethylamine N-oxide and betaine,

84 nificant reduction of Lp(a) levels following L-carnitine supplementation (WMD: -8.82 mg/dL, 95% CI: -

85 this study was to determine the efficacy of L-carnitine supplementation as a treatment for fatigue i

86 Four weeks of 2 g of L-carnitine supplementation did not improve fatigue in p

87 Chronic dietary L-carnitine supplementation in mice altered cecal microb

88 nts were randomly assigned to treatment with L-carnitine supplementation or placebo.

89 L-carnitine supplementation resulted in significant carn

90 provement in fatigue or other outcomes after L-carnitine supplementation.

91 cidate the clinical value and safety of oral L-carnitine supplementation.

92 uggests a significant Lp(a) lowering by oral L-carnitine supplementation.

93 Finally, similarly to glucocorticoids, L-carnitine suppressed tumor necrosis factor-alpha (TNFa

94 nvolved in cardiac metabolism: coenzyme Q10, l-carnitine, thiamine, and amino acids, including taurin

95 vegans or vegetarians following ingestion of L-carnitine through a microbiota-dependent mechanism.

96 trial design for evaluating the addition of L-carnitine to the treatment of vasopressor-dependent se

97 zygous for the -207G allele showed increased l-carnitine transport compared with the -207C/C homozygo

98 Leu polymorphism showed a reduced V(max) for l-carnitine transport to approximately 50% of the refere

99 nd intervention (from 4 to 8 mo) with acetyl-L-carnitine treatment normalized nerve PGE(1) whereas 6-

100 Acetyl-L-carnitine treatment promoted nerve fiber regeneration,

101 -mediated pathway plays a role in regulating L-carnitine uptake by Caco-2 cells.

102 L-carnitine uptake by intestinal epithelial cells (Caco-

103 L-Carnitine uptake was also energy-dependent, being sign

104 [3H]-L-carnitine uptake was linear and appreciable for up to

105 gues significantly (P < 0.01) inhibited [3H]-L-carnitine uptake, whereas unrelated compounds were ine

106 s to clarify the mechanism and regulation of L-carnitine uptake.

107 At the same concentrations, L-carnitine was able to trigger nuclear translocation of

108 vention with intravenous rather than enteral L-carnitine was associated with the greatest hepatic sur

109 Uptake of [3H]-L-carnitine was measured across the apical membrane of c

110 chondrial respiration supported by palmitoyl-l-carnitine was significantly lower in POAF patients and

111 transactivation and cytokine suppression by L-carnitine were abrogated by the GRalpha-antagonist RU

112 ted encouraging data regarding the action of L-carnitine when added to AS-3.

113 ogenous antioxidant glutathione), and acetyl-L-carnitine (which prevents Abeta-induced mitochondrial

114 e conversion of gamma butyrobetaine (GBB) to l-carnitine, which is involved in the generation of meta

115 Millimolar concentrations of L-carnitine, which were not cytotoxic in vitro, signific

116 y consisted of a 5-h intravenous infusion of l-carnitine while circulating insulin was maintained at

117 10.29, -7.72, p < 0.001) but not intravenous L-carnitine (WMD: -2.91 mg/dL, 95% CI: -10.22, 4.41, p =